VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ONCO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ONCOOnconetix, Inc.
$3.21$1M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
ONCO logo

Onconetix, Inc.

ONCO
NASDAQ · Diagnostics & Lab Testing
$3.21
At close - Nov 13, 4:00 PM EST - USD
Market Cap$1M
P/E-0.1x
52W High$1610.00
Volume69.68K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Commercial Collapse Threatens Onconetix Operational Survival

Onconetix faces a critical existential threat as its primary Entadfi product launch has failed to gain traction, evidenced by a 78.9% year-over-year revenue decline in 2026Q1.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

ONCO price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

2/12 Beats

EPS beat 2 of last 12 quarters

02

Valuation risk

-100% Peers

P/E is 100% below peer median

03

Market leadership

RS 4 · Lag

Laggard (Underperforming 96% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Aug 13

Market performance

Price History →

Trailing total returns as of 11/16/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
ONCO-99.60%
S&P 500 (^GSPC)+10.42%
1-Year Return
ONCO-99.74%
S&P 500 (^GSPC)+12.25%
3-Year Return
ONCO-100.00%
S&P 500 (^GSPC)+71.83%
5-Year Return
ONCO-100.00%
S&P 500 (^GSPC)+61.39%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$815K-67.7% YoY
Net income FY25
-$14M+76.1% YoY
Free cash flow FY25
-$10M+8.0% YoY
Operating margin FY25
-778.2%+1459.8 pts YoY
ROIC (FY25)-32.8%
Avg ROIC 5Y-657.7%
ROE (TTM)-92%
Piotroski Score5 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate2/12 (67%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026Latest
May 13, 2026
-$6.71
vs —
$21,457
vs —
Q2 2026
Mar 12, 2026
$12.58
vs —
$303,596
vs —
Q4 2025
Nov 13, 2025
-$6.25
vs —
$303,651
vs —
Q3 2025
Aug 14, 2025
-$4.05
vs —
$106,494
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Defense World·4d ago
Celularity (NASDAQ:CELU) and Onconetix (NASDAQ:ONCO) Financial Contrast

Onconetix (NASDAQ: ONCO - Get Free Report) and Celularity (NASDAQ: CELU - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership. Volatility and Risk Onconetix has a beta of 2.62,

Business Wire·Nov 9, 2026
Realbotix Provides Update on Nasdaq Listing Timeline

LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Parent Company”), a manufacturer of humanoid robots and AI systems, announces that it has extended the outside date for completion of its all-stock merger transaction between Realbotix LLC (“RealLLC” or the “Subsidiary”), a wholly owned subsidiary of Realbotix, and Onconetix, Inc. (NASDAQ: ONCO) (“ONCO”) to March 31, 2027. “We appreciate shareholder patience as we move closer to compl.

GlobeNewsWire·Oct 27, 2026
Onconetix Acquisition Target Realbotix Launches Echo Humanoid Robot Line with Tabletop and Full Body Models Designed for Education, Wellness, and Social Engagement

Echo Tabletop Priced at $11,950 and Echo Full Body at $59,950; First Production Run of 250 Units Available for 2027 Delivery; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.

GlobeNewsWire·Oct 26, 2026
Onconetix Announces Reverse Stock Split

CINCINNATI, Ohio, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”), today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of the Company's outstanding common stock. The reverse split is expected to become effective at 12:01 a.m. Eastern Time on November 6, 2026. The Company's common stock has been assigned a new CUSIP number, 68237Q500, in connection with the reverse stock split.

Filtered for Onconetix, Inc.More Headlines
04

Compare before deciding

Benchmark ONCO against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Onconetix, Inc. (ONCO)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ONCO logoONCOOnconetix, Inc.Current
$3.21$1.15M-0.07-67.7%-1578.79%-91.95%—
CRVS logoCRVSCorvus Pharmaceuticals, Inc.
$10.64$894.72M-15.30——-34.98%—
AGEN logoAGENAgenus Inc.
$6.73$280.25M19.9510.37%20.98%——
IMVT logoIMVTImmunovant, Inc.
$34.18$7.05B-13.88—-7173.52%-63.01%—
PRAX logoPRAXPraxis Precision Medicines, Inc.
$328.13$9.15B-26.64-100%—-29.41%—
JANX logoJANXJanux Therapeutics, Inc.
$11.37$693.39M-7.18-5.55%-428.74%-10.68%—

Compare ONCO vs Peers

Onconetix, Inc. (ONCO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CRVS

Most directly comparable listed peer for ONCO.

Scale Benchmark

vs IQV

Larger-name benchmark to compare ONCO against a more recognizable public peer.

Peer Set

Compare Top 5

vs CRVS, AGEN, IMVT, PRAX

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

ONCO SEC Filings & Documents

Onconetix, Inc. (ONCO) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Jul 29, 2026·SEC

Material company update

May 19, 2026·SEC

Material company update

May 14, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 13, 2026·SEC

FY 2025

Jun 2, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 13, 2026·SEC

FY 2026

May 13, 2026·SEC

FY 2025

Nov 13, 2025·SEC

Get notified when ONCO posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ONCO Frequently Asked Questions

Onconetix, Inc. (ONCO) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Onconetix, Inc.'s revenue?

Onconetix, Inc. (ONCO) reported $0.6M in revenue over the trailing twelve months. Revenue was $0.8M in fiscal year 2025.

How fast is Onconetix, Inc. growing?

Onconetix, Inc. (ONCO) revenue fell by 51.3% over the trailing twelve months, compared with the twelve months before.

Is ONCO profitable?

No. Onconetix, Inc. (ONCO) reported a net loss of $10.2M over the trailing twelve months.

Dividend & Returns
What is ONCO's return on equity?

Onconetix, Inc. (ONCO) had a return on equity (ROE) of -92.0% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Onconetix, Inc.'s free cash flow?

Onconetix, Inc. (ONCO) had negative free cash flow of $10.3M over the trailing twelve months.

What if you invested $1,000 in ONCO back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →